150 related articles for article (PubMed ID: 29238994)
1. Intestinal P-glycoprotein inhibitors, benzoxanthone analogues.
Chae SW; Lee J; Park JH; Kwon Y; Na Y; Lee HJ
J Pharm Pharmacol; 2018 Feb; 70(2):234-241. PubMed ID: 29238994
[TBL] [Abstract][Full Text] [Related]
2. Xanthone analogues as potent modulators of intestinal P-glycoprotein.
Chae SW; Woo S; Park JH; Kwon Y; Na Y; Lee HJ
Eur J Med Chem; 2015 Mar; 93():237-45. PubMed ID: 25686592
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Lee CK; Ki SH; Choi JS
Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
[TBL] [Abstract][Full Text] [Related]
5. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
Lee K; Chae SW; Xia Y; Kim NH; Kim HJ; Rhie S; Lee HJ
Eur J Pharmacol; 2014 Jan; 723():381-8. PubMed ID: 24252806
[TBL] [Abstract][Full Text] [Related]
6. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
8. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
Zhang Y; Wang C; Liu Z; Meng Q; Huo X; Liu Q; Sun P; Yang X; Sun H; Ma X; Liu K
Pharmacol Rep; 2018 Apr; 70(2):243-250. PubMed ID: 29475007
[TBL] [Abstract][Full Text] [Related]
9. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of phenylbutenoid dimers as inhibitors of P-glycoprotein.
Chae SW; Han AR; Park JH; Rhie JY; Lim HJ; Seo EK; Lee HJ
J Nat Prod; 2013 Dec; 76(12):2277-81. PubMed ID: 24266329
[TBL] [Abstract][Full Text] [Related]
11. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
12. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
Yang S; Gursoy RN; Lambert G; Benita S
Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
[TBL] [Abstract][Full Text] [Related]
14. Newly Synthesized Oxygenated Xanthones as Potential P-Glycoprotein Activators:
Martins E; Silva V; Lemos A; Palmeira A; Puthongking P; Sousa E; Rocha-Pereira C; Ghanem CI; Carmo H; Remião F; Silva R
Molecules; 2019 Feb; 24(4):. PubMed ID: 30781374
[TBL] [Abstract][Full Text] [Related]
15. Self-assembled micelles based on N-octyl-N'-phthalyl-O-phosphoryl chitosan derivative as an effective oral carrier of paclitaxel.
Qu G; Hou S; Qu D; Tian C; Zhu J; Xue L; Ju C; Zhang C
Carbohydr Polym; 2019 Mar; 207():428-439. PubMed ID: 30600025
[TBL] [Abstract][Full Text] [Related]
16. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
17. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
[TBL] [Abstract][Full Text] [Related]
18. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
19. Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats.
Kim KM; Lee K; Jang K; Moon YS; Lee HJ; Rhie SJ
Biomol Ther (Seoul); 2017 Sep; 25(5):553-558. PubMed ID: 28173641
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
